

PATIENT							
Name	██████████	MRN	██████████	DOB	██████████	Gender	██████████
ORDER INFORMATION							
Order ID	██████████	Provider	██████████	Practice	██████████		
Indication	C34.90, Malignant neoplasm of unsp part of unsp bronchus or lung, Stage IIIA			Report Date	██████████		
TEST SPECIMEN							
Specimen ID	██████████	Specimen Source	core biopsy, LLL lung mass	Collected	██████████		
Specimen Facility	██			Received	██████████		

DETECTED VARIANTS								
Variant	Exon	VAF	Therapies Associated With Tumor Type	Priority Precision Medicine Trials	Additional Precision Medicine Trials	Potential Off-Label Therapies	Potential Hereditary Variants	Variants of Unknown Therapeutic Significance
EML4e6-ALKe20 Fusion	-	-	◇	◇	◇			
TP53 c.604C>G (R202G)	6	0.12			◇			◇
STK11 c.242delA (K81RfsX15)	1	0.13						◇

VAF = Variant Allele Frequency

THERAPEUTIC BENEFIT SUMMARY		
Therapies Associated with Non-Small Cell Lung Cancer		
Variant Detected:	EML4e6-ALKe20 Fusion	
Therapies	Level of Evidence	Evidence Sources
alectinib	Consensus	EMA-alectinib, ESMO-Metastatic Non-Small-Cell Lung Cancer, FDA-alectinib, NCCN-Non-Small Cell Lung Cancer
brigatinib	Consensus	FDA-brigatinib, NCCN-Non-Small Cell Lung Cancer
ceritinib	Consensus	EMA-ceritinib, ESMO-Metastatic Non-Small-Cell Lung Cancer, FDA-ceritinib, NCCN-Non-Small Cell Lung Cancer
crizotinib	Consensus	EMA-crizotinib, ESMO-Metastatic Non-Small-Cell Lung Cancer, FDA-crizotinib, NCCN-Non-Small Cell Lung Cancer
crizotinib + radiation therapy	Consensus	ESMO-Metastatic Non-Small-Cell Lung Cancer
crizotinib + surgical intervention	Consensus	ESMO-Metastatic Non-Small-Cell Lung Cancer
EGFR tyrosine kinase inhibitor	Not Recommended	NCCN-Non-Small Cell Lung Cancer